In this interview segment from WallStreetCast Show #23, Neil Lyons, Chief Financial Officer of Cleveland BioLabs, talks with Steve Crowley about the company’s development of a drug for radiation exposure, which also is having applications as a cancer treatment.
CBLI has several unique approaches to boosting the body's natural immune systems in fighting cancers; Curaxins are being developed as anti-cancer agents.
The company’s ticker on the NASDAQ is CBLI. The web site is cbiolabs.com.
Loading more stuff…
Hmm…it looks like things are taking a while to load. Try again?